PROMIFOX, NCT04729205: Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies |
|
|
| Terminated | 1b | 9 | RoW | Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug, Folfox | Lipomedix Pharmaceuticals Inc. | Cancer, Gastro-Intestinal Intraepithelial Neoplasia | 09/23 | 09/23 | | |
NCT02648711: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors |
|
|
| Terminated | 1 | 41 | US | CRLX101, NLG207, Bevacizumab, Avastin, mFOLFOX6, oxaliplatin, leucovorin, 5FU | NewLink Genetics Corporation | Solid Tumors | 10/17 | 05/18 | | |
CCGLC-007, NCT05533892: Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC |
|
|
| Recruiting | 1 | 30 | RoW | Nocardia rubra cell wall skeleton, N-CWS, Hepatic arterial infusion chemotherapy, HAIC, Lenvatinib, JieLiEn, Tislelizumab, BaiZeAn | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, M&R Pharm, Geneplus-Beijing Co. Ltd., Yuce Biotechnology Co., Ltd., Geneis, Simcere Pharmaceutical Co., Ltd, BeiGene, Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 02/25 | | |
